EcoDrugPlus

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSSVLG00005013367
Gene Symbol: OPRL1
1 Cross references
199 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSSVLG00005025596
Gene Symbol: OXTR
1 Cross references
262 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSSVLG00005025284
Gene Symbol: PAK4
1 Cross references
163 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSSVLG00005022129
Gene Symbol: PTH1R
1 Cross references
196 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSSVLG00005006748
Gene Symbol: PPARA
1 Cross references
453 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSSVLG00005008351
Gene Symbol: PPARD
1 Cross references
418 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSSVLG00005020780
Gene Symbol: PPARG
1 Cross references
405 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSSVLG00005007992
Gene Symbol: PIK3CA
1 Cross references
275 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSSVLG00005004541
Gene Symbol: PIK3CD
1 Cross references
213 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSSVLG00005024115
Gene Symbol: PIK3CG
1 Cross references
213 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSSVLG00005010372
Gene Symbol: PDE10A
1 Cross references
205 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSSVLG00005020997
Gene Symbol: PDE3A
1 Cross references
272 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).